Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases.
Hemogenyx Pharma Plc (HEMO.L) Lease of New York Mink Building Custom Laboratory
Hemogenyx Pharmaceuticals has signed a lease with The Janus Property Company (“Janus”) for a new custom-designed and built laboratory in the Mink Building, located in the Manhattanville Factory District of
Hemogenyx Pharma Plc (HEMO.L) CDX Licence Agreement
Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, announces that it has signed a licence agreement (the “Agreement”) with the global biopharmaceutical
Hemogenyx Pharma Plc (HEMO.L) U.S. Approval and Issuance of CDX Antibody Patent
Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, is pleased to announce that a patent application.
Hemogenyx Pharma Plc (HEMO.L) Termination of Mint Facility; Admission of Shares
Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for deadly blood diseases, announces that, pursuant to the redemption, sale and conversion of convertible unsecured loan
Dr Vladislav Sandler, CEO & Co-Founder of Hemogenyx Pharmaceuticals (HEMO.L) Interview
H.C. Wainwright Investment Conference
Tirupati Graphite (TGR.L) set to follow IPO winners Pensana (PRE.L) and Kistos (KIST.L)
2020 has not exactly been a great year for IPOs. The pandemic has meant two things.
Shishir Poddar, CEO Tirupati Graphite (TGR.L) Interview
So Tirupati is slightly unusual because they’ve launched a first of its kind IPO offer for retail investors via PrimaryBid, providing retail with the same investment opportunity and terms as
Dev Clever Holdings PLC (DEV.L) Ready For A “Week On, One Week Off” School Era
The Coronavirus pandemic has had a massive impact on the UK economy. A contraction of more than 20 per cent in the three months to June, means that we are
Pires Investments PLC (PIRI.L) Nicholas Lee, Non-Executive Director, Podcast
Pires Investments plc (AIM: PIRI), the investment company focused on next generation technology, is pleased to announce its unaudited interim results for the six-month period ended 30 April 2020.
Pires Investments (PIRI.L): Is It Finally Time To Value Tech Investment Companies
As Highly As Their Investments?